[1]
Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield processes in relapsing-remitting multiple sclerosis (SELECTION): a multicenter, randomized, double-blind extension trial. Lancet Neurol 2014; 13: 472-81.
[2]
Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol 2014; 262 Pt A: 44-51.
[3]
Liu J, Wang LN, Zhan S, Xia Y. Daclizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2013; 12CD008127
[4]
Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013; 10: 55-67.
[5]
He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2013; 6; 12:: CD009130.
[6]
Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Exp Rev Neurother 2010; 10: 791-809.
[7]
Deiß A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Exp Rev Neurother 2013; 13: 313-35.
[8]
Knier B, Hemmer B, Korn T. Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opin Biol Ther 2014; 14: 503-13.
[9]
Gupta S, Weinstock-Guttman B. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango. Expert Opin Biol Ther 2014; 14: 115-26.
[10]
McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs 2013; 73: 1463-81.
[11]
Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 2012; 71: 604-17.
[12]
Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8: 31-45.
[13]
Hartung HP, Aktas O, Boyko AN. Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015; 21: 22-34.
[14]
Jones DE, Goldman MD. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. Exp Rev Clin Immunol 2014; 10: 1281-91.
[15]
Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015; 86: 208-15.
[16]
Willis MD, Robertson NP. Alemtuzumab for the treatment of multiple sclerosis. Ther Clin Risk Manag 2015; 11: 525-34.
[17]
Hersh CM, Cohen JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy 2014; 6: 249-59.
[18]
D’Amico E, Messina S, Caserta C, Patti F. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opin Drug Saf 2015 Mar 31; 1-12. [Epub ahead of print].
[19]
Oh J, Saidha S, Cortese I, et al. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology 2014; 82: 984-8.
[20]
Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 2012; 142: 9-14.
[21]
Melcon MO, Melcon CM, Bartoloni L, et al. Towards establishing MS prevalence in Latin America and the Caribbean. Mult Scler 2013; 19: 145-52.